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Abstract
Somatic mutations in protein kinases (PKs) are frequent driver events in many human
tumors, while germ-line mutations are associated with hereditary diseases. Here we pre-
sent Kin-driver, the first database that compiles driver mutations in PKs with experimental
evidence demonstrating their functional role. Kin-driver is a manual expert-curated data-
base that pays special attention to activating mutations (AMs) and can serve as a validation
set to develop new generation tools focused on the prediction of gain-of-function driver
mutations. It also offers an easy and intuitive environment to facilitate the visualization and
analysis of mutations in PKs. Because all mutations are mapped onto a multiple sequence
alignment, analogue positions between kinases can be identified and tentative new muta-
tions can be proposed for studying by transferring annotation. Finally, our database can
also be of use to clinical and translational laboratories, helping them to identify uncommon
AMs that can correlate with response to new antitumor drugs. The website was developed
using PHP and JavaScript, which are supported by all major browsers; the database was
built using MySQL server. Kin-driver is available at: http://kin-driver.leloir.org.ar/
Introduction
Cancer arises due to somatic mutations that result in a
growth advantage for the tumor cells. These mutations are
known as ‘drivers’ and can be divided into two groups:
(i) ‘loss-of-function’ mutations, which inactivate tumor
suppressor genes (from here on ‘inactivating mutations’)
and (ii) ‘activating’ or ‘gain-of-function’ mutations that
transform proto-oncogenes into oncogenes. Somatic muta-
tions in protein kinases (PKs) are frequent driver events in
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many human tumor types and functionally relevant germ-
line mutations are associated with hereditary disorders.
Clinical laboratories worldwide are analysing thou-
sands of human tumor samples, looking for activating
mutations (AMs) in certain PKs—such as EGFR, HER2 or
BRAF—that correlate with good responses to new gener-
ations of antitumor drugs that are kinase inhibitors.
Mutations either new or not functionally characterized are
often found. In addition, whole-genomic sequencing
of human malignancies and other diseases is identifying
thousands of changes in PKs, but most of them are likely
to be passenger mutations or even polymorphisms.
Discriminating driver mutations in PKs is a significant
challenge that is hampered by the fact that there are no
curated sets of true driver and passenger alterations. The
extent of this challenge was evidenced when three state-of-
the-art methods, namely MutationAssessor (1), TransFITC
(2) and FATHMM (3), were fed with well-established,
tumor-associated AMs of PKs and failed to predict them as
high impact or disease related (4). Therefore, it is uncertain
that the current tools, which are generally based on conser-
vation calculations, can be trusted to screen whole-genome
sequencing data in search of driver mutations in PKs. New
methods need to be developed and unambiguously assessed




Recruitment procedure is described by Molina-Vila et al.
(4). Briefly, in the case of proto-oncogenic kinases, ab-
stracts and titles of PubMed manuscripts were mined with
the kinase name, plus words ‘activating’, ‘gain of function’
or ‘constitutive activation’. For tumor suppressor kinases,
the words ‘inactivating’ and ‘loss of function’ were used.
Furthermore, all UniProt entries for human kinases
were mined for the same keywords to identify new vari-
ants. The references were manually checked to confirm its
status.
For each annotated mutation, all samples with that mu-
tation were retrieved from COSMIC using the Biomart
perl API.
MSA construction
Human STK and TKs domains were obtained from Pfam
families PF00069 and PF07714, respectively. To account
for classification problems in Pfam families, some se-
quences incorrectly classified as TK were moved from this
alignment to the corresponding one and realigned with
T-coffee (5). For each MSA, a sequence logo was calcu-
lated using seq2logo (6).
Mutation relative frequency calculation
A relative frequency was computationally calculated for all
mutations of the 518 PKs of the COSMIC database release
70 (7) as the frequency of mutation in COSMIC for that
gene times 1000 over the total number of tumor samples
sequenced for that gene.
All mutations with a relative frequency above 2 (0.2%)
were then checked in PubMed by introducing the name of
the mutation (e.g. P267R) and added to the dataset if they
were found to have functional effects. EGFR mutations
conferring a response rate to erlotinib higher than 50%,
according to the EGFR somatic mutations database (http://
www.somaticmutations-egfr.info/), were also added.
Results
Kin-Driver database offers a comprehensive set of 560 pri-
mary AMs in the kinase and justamembrane (JM) domains
of 39 PKs and 83 inactivating mutations in 5 kinases com-
piled by a two-step systematic search for each of the 518
PKs present in the ‘complete kinase’ study of the COSMIC
database (7) (release 70). Only primary mutations with
experimental evidence demonstrating their activating/
inactivating role were included.
Kin-Driver is a MySQL relational database offering
structural and sequence data cross-referenced with
COSMIC and with our set of curated mutations. It also
provides the frequencies of these mutations in actual tumor
samples. The CosmicMart service is used to fetch the data,
so frequencies for new mutations can easily be added and
data are kept up to date with the periodic COSMIC
releases.
Our database can be interrogated by protein name,
gene name or keyword, amino acid position or specific mu-
tation name (i.e. T790M). Range or specific mutations can
also be used to look for driver mutations in other PKs in
equivalent positions (see later). Finally, the database can
be browsed by PK name, domain, tissue or type of hist-
ology, and these last two attributes obtained from the cor-
responding mutated samples are available in the COSMIC
database.
Each individual mutation in Kin-Driver is displayed
with its validation status (‘activating’, ‘inactivating’ or ‘un-
known’), the mutation type (missense, insertion, deletion,
nonsense, frameshift or indel), its absolute and relative fre-
quencies in human tumors and the PubMed reference
describing that particular mutation as activating/inactivat-
ing. Mutations can also be visualized in a multiple
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sequence alignment (MSA), placing on top the protein of
interest and highlighting the mutation (Figure 1). The PK
sequences are classified into one of the two families: tyro-
sine kinases (TKs, E.C number: 2.7.10.- classification) and
serine/threonine kinases (STK, E.C number 2.7.11.-). Each
family has its own MSA. The boundaries of the kinase do-
mains are those defined either by Pfam (8) or Uniprot (9).
The three-dimensional structure of the protein (when avail-
able) marking the mutated position is also shown (Figure
2A). As an example, the output of Kin-Driver for mutation
EGFR E746-A750del is presented in Figures 1 and 2.
In case the user challenges Kin-Driver with a particular
mutation or position that is not described as activating/
inactivating in our dataset, our server retrieves if there is
an activating/inactivating mutation in any other human
kinase in an equivalent position (based on the MSA align-
ment). For example, human EGFR in position 724 has no
mutation described, but ALK has one AM in the equivalent
position G1128A.
Another interesting feature of Kin-Driver is that it in-
corporates the recent finding that AMs are not randomly
distributed within the kinase domain, but cluster in
relatively short ‘hyper-mutated’ segments (HSs) (4). In the
case of TKs, our server shows the location of the mutation
or position interrogated in a central moving average plot
(cmap), allowing users to inspect whether it is located
within a HS (Figure 2B). The cmap is calculated by adding
columnwise all the relative frequencies of all mutations
mapped in the MSA obtaining a value per column of the
alignment. Then, for each position of the MSA, an average
of these values is calculated using a windows size n¼ 13
(Figure 1). Newly discovered mutations, or those of yet un-
known effects, that are located within one of the HSs can
be suspected to be activating. Therefore, they might be
worth further analysis or, if they affect a druggable kinase,
might predict a good response to the corresponding antitu-
mor drug (10, 11).
Finally, the possibility to browse Kin-Driver by tissue
and histology is also of interest. First, it allows making
instant comparisons. For example, it reveals that
hematopoietic and lymphoid tumors show the highest fre-
quency of AMs (33.25%), followed by lung (11.96%). For
lung tumors, the more frequently mutated kinase is EGFR,
with 61 of the 95 described AMs. Second, this kind of
Figure 1. Snapshot of the Kin-Driver EGFR E746-A750del output. MSA logo showing position conservation and MSA highlighting the position of the
selected mutation (gray background). Red boxes indicate AMs.
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browsing can be useful to clinical laboratories; when con-
fronted with a tumor sample, they can use Kin-Driver
to find the genes affected by actionable mutations in this
particular type of neoplasia, and they can subsequently
direct their efforts to the analysis of those genes.
Although mutational data on PKs are currently cata-
loged in several databases (7, 12–14), they do not discrim-
inate passengers from drivers. Kin-Driver is unique in
offering a curated functional annotation, supported by ex-
perimental data. Also, the possibility of transferring the
mutation to equivalent positions in homologous proteins
through an MSA and the mapping into the desired protein
structure with the Jsmol app (15) are unique features
of our database. In contrast, COSMIC (7) is the most
comprehensive compilation of somatic mutations, but no
functional status is given, no equivalences between PKs can
be inferred, nor the position in the structure is shown.
ProKinO (12) provides a kinase ontology and integrates
basic mutational data (as recruited from COSMIC) with
other types of data, but they do not offer functional or
structural information. MoKCa and Canpredict (13, 14)
offer a prediction of ‘cancer-associated’ mutations, but it is
not based on experimental evidence and the pictures of the
mutations in the protein structures are static. Finally,
KinMutBase (16) has no information on activation status
and is outdated.
Figure 2. Snapshot of the Kin-Driver EGFR E746-A750del output. (A) Mutation EGFR E746-A750del mapped onto the structure of the selected human
EGFR (pdb code 1M14). Other structures can be chosen for mapping. (B) Location of the mutation in a cmap plot (n¼ 13).
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Conclusions
To the best of our knowledge, Kin-Driver is the first com-
prehensive curated dataset of driver mutations in human
cancer. It compiles data otherwise disseminated in several
databases that offer poor functional information and in hun-
dreds of articles describing the effects of one or a few muta-
tions each. Our database can be used as a gold standard to
develop and validate new bioinformatics methods to predict
driver mutations. Second, it sets an easy and intuitive envir-
onment for the visualization and analysis of mutations in
PKs. And third, it can help researchers and clinicians to rec-
ognize relevant mutations in human malignancies.
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